| Francis Kwarteng, MD | |
|
401 S. Madison Street, Albany, GA 31701 | |
| (229) 888-3636 | |
| (229) 888-5535 |
| Full Name | Francis Kwarteng |
|---|---|
| Gender | Male |
| Speciality | Obstetrics & Gynecology |
| Location | 401 S. Madison Street, Albany, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851551923 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 061792 (Georgia) | Primary |
| Entity Name | Azalea Womens Center, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710194097 PECOS PAC ID: 7517952302 Enrollment ID: O20040420000423 |
News Archive
While about a quarter of physicians and researchers working in advanced heart failure (HF) and transplant cardiology are women, representation of women leading HF research remains limited, according to new research led by Penn Medicine.
The first genetic marker for the bone tumor, osteoblastoma, has been discovered by scientists at the Wellcome Sanger Institute and their collaborators.
Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).
Researchers have found a mutation in the gene for the growth hormone receptor that promotes longevity, increasing men's lifespan by an average of 10 years.
› Verified 8 days ago
| Entity Name | Hospital Authority Of Liberty County |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326079260 PECOS PAC ID: 5799772190 Enrollment ID: O20040428000377 |
News Archive
While about a quarter of physicians and researchers working in advanced heart failure (HF) and transplant cardiology are women, representation of women leading HF research remains limited, according to new research led by Penn Medicine.
The first genetic marker for the bone tumor, osteoblastoma, has been discovered by scientists at the Wellcome Sanger Institute and their collaborators.
Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).
Researchers have found a mutation in the gene for the growth hormone receptor that promotes longevity, increasing men's lifespan by an average of 10 years.
› Verified 8 days ago
| Entity Name | Southern Ob Gyn Associates P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801951454 PECOS PAC ID: 8729059043 Enrollment ID: O20040802000950 |
News Archive
While about a quarter of physicians and researchers working in advanced heart failure (HF) and transplant cardiology are women, representation of women leading HF research remains limited, according to new research led by Penn Medicine.
The first genetic marker for the bone tumor, osteoblastoma, has been discovered by scientists at the Wellcome Sanger Institute and their collaborators.
Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).
Researchers have found a mutation in the gene for the growth hormone receptor that promotes longevity, increasing men's lifespan by an average of 10 years.
› Verified 8 days ago
| Entity Name | Robert T Stark Md,pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053342774 PECOS PAC ID: 5799798880 Enrollment ID: O20060712000199 |
News Archive
While about a quarter of physicians and researchers working in advanced heart failure (HF) and transplant cardiology are women, representation of women leading HF research remains limited, according to new research led by Penn Medicine.
The first genetic marker for the bone tumor, osteoblastoma, has been discovered by scientists at the Wellcome Sanger Institute and their collaborators.
Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).
Researchers have found a mutation in the gene for the growth hormone receptor that promotes longevity, increasing men's lifespan by an average of 10 years.
› Verified 8 days ago
| Entity Name | Obhg Georgia, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750686838 PECOS PAC ID: 9032383583 Enrollment ID: O20111117000602 |
News Archive
While about a quarter of physicians and researchers working in advanced heart failure (HF) and transplant cardiology are women, representation of women leading HF research remains limited, according to new research led by Penn Medicine.
The first genetic marker for the bone tumor, osteoblastoma, has been discovered by scientists at the Wellcome Sanger Institute and their collaborators.
Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).
Researchers have found a mutation in the gene for the growth hormone receptor that promotes longevity, increasing men's lifespan by an average of 10 years.
› Verified 8 days ago
| Entity Name | Dhp Of Georgia Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578826988 PECOS PAC ID: 9931358520 Enrollment ID: O20120925000305 |
News Archive
While about a quarter of physicians and researchers working in advanced heart failure (HF) and transplant cardiology are women, representation of women leading HF research remains limited, according to new research led by Penn Medicine.
The first genetic marker for the bone tumor, osteoblastoma, has been discovered by scientists at the Wellcome Sanger Institute and their collaborators.
Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).
Researchers have found a mutation in the gene for the growth hormone receptor that promotes longevity, increasing men's lifespan by an average of 10 years.
› Verified 8 days ago
| Entity Name | Sgmc Physician Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417597170 PECOS PAC ID: 4082036843 Enrollment ID: O20201015000629 |
News Archive
While about a quarter of physicians and researchers working in advanced heart failure (HF) and transplant cardiology are women, representation of women leading HF research remains limited, according to new research led by Penn Medicine.
The first genetic marker for the bone tumor, osteoblastoma, has been discovered by scientists at the Wellcome Sanger Institute and their collaborators.
Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).
Researchers have found a mutation in the gene for the growth hormone receptor that promotes longevity, increasing men's lifespan by an average of 10 years.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Francis Kwarteng, MD 204 N Westover Blvd, Albany, GA 31707-2983 Ph: (229) 888-6559 | Francis Kwarteng, MD 401 S. Madison Street, Albany, GA 31701 Ph: (229) 888-3636 |
News Archive
While about a quarter of physicians and researchers working in advanced heart failure (HF) and transplant cardiology are women, representation of women leading HF research remains limited, according to new research led by Penn Medicine.
The first genetic marker for the bone tumor, osteoblastoma, has been discovered by scientists at the Wellcome Sanger Institute and their collaborators.
Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).
Researchers have found a mutation in the gene for the growth hormone receptor that promotes longevity, increasing men's lifespan by an average of 10 years.
› Verified 8 days ago
April L Reese, CNM Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2701 Meredyth Dr, Albany, GA 31707 Phone: 229-883-7010 Fax: 229-430-9220 | |
Dr. Sheena Elois Favors, D.O, M.S Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2100 Palmyra Rd, Albany, GA 31701 Phone: 229-888-3636 Fax: 229-888-5535 | |
Donna Graf, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2701 Meredyth Dr, Albany, GA 31707 Phone: 229-883-7010 Fax: 229-435-4022 | |
Mr. Paul Andrew Smurda, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 414 5th Ave, Albany, GA 31701 Phone: 229-883-4555 Fax: 229-888-0063 | |
Dr. Jeffrey Warren Ellis, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2701 Meredyth Dr, Albany, GA 31707 Phone: 229-430-9213 Fax: 229-903-1585 | |
Dr. Michael Scott Edwards, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 417 W 3rd Ave, Albany, GA 31701 Phone: 229-312-2557 Fax: 229-312-2555 | |
Yung Chun Tsai, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 421 W 4th Ave, Albany, GA 31701 Phone: 229-435-0002 Fax: 229-883-1782 |